|
| Index | - | P/E | 68.43 | EPS (ttm) | 0.13 | Insider Own | 96.20% | Shs Outstand | 13.18M | Perf Week | -8.72% |
| Market Cap | 1.24B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.00% | Shs Float | 5.30M | Perf Month | 149.00% |
| Income | 1.80M | PEG | - | EPS next Q | - | Inst Own | 9.20% | Short Float / Ratio | 4.49% / 1.20 | Perf Quarter | -16.60% |
| Sales | 34.38M | P/S | 36.08 | EPS this Y | - | Inst Trans | -10.52% | Short Interest | 0.24M | Perf Half Y | -15.14% |
| Book/sh | 6.78 | P/B | 1.28 | EPS next Y | - | ROA | 1.30% | Target Price | - | Perf Year | -13.45% |
| Cash/sh | 0.00 | P/C | - | EPS next 5Y | - | ROE | 1.60% | 52W Range | 2.87 - 11.69 | Perf YTD | 117.79% |
| Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -25.66% | Beta | - |
| Dividend % | - | Quick Ratio | 0.20 | Sales past 5Y | - | Gross Margin | - | 52W Low | 202.79% | ATR | 1.58 |
| Employees | 2 | Current Ratio | 0.20 | Sales Q/Q | 36.70% | Oper. Margin | - | RSI (14) | 57.59 | Volatility | 34.75% 27.09% |
| Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | 88.10% | Profit Margin | - | Rel Volume | 1.76 | Prev Close | 8.81 |
| Shortable | No | LT Debt/Eq | 0.00 | Earnings | - | Payout | 0.00% | Avg Volume | 197.58K | Price | 8.69 |
| Recom | - | SMA20 | 21.00% | SMA50 | 56.70% | SMA200 | -4.06% | Volume | 347,734 | Change | -1.36% |
 | ||||
| ||||
|
||||
| ||||
| Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc. | ||||
| ||||
|
| open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite